STROMECTOL (Ivermectin) is a semisynthetic, anthelmintic agent for oral administration. Ivermectin is derived from the avermectins, a class of highly active broad-spectrum, antiparasitic agents isolated from the fermentation products of Streptomyces avermitilis.
Ivermectin is a mixture containing at least 90% 5-Odemethyl-22,23-dihydroavermectin A1a and less than 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro25-(1-methylethyl)avermectin A1a, generally referred to as 22,23-dihydroavermectin B1a and B1b, or H2B1a and H2B1b, respectively
The U.S. FDA approves ivermectin tablets to treat people with intestinal strongyloidiasis and onchocerciasis, two conditions caused by parasitic worms. In addition, some topical forms of Ivermectin are approved to treat external parasites like head lice and for skin conditions such as rosacea.
Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract. Ivermectin is indicated for treating intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of Ivermectin. In addition, Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus.
Ivermectin Use Against COVID-19
Ivermectin is not authorized or approved by the U.S. FDA for the prevention or treatment of COVID-19. In addition, the U.S. National Institutes of Health's COVID-19 Treatment Guidelines Panel has also determined that there are currently insufficient data to recommend Ivermectin for the treatment of COVID-19.
On October 19, 2021, the Canadian government issued a notice saying, 'Ivermectin not authorized to prevent or treat COVID-19 and may cause serious health problems.'
Ivermectin Revenues 2021
The JAMA Network published a Letter of January 13, 2022 - US Insurer Spending on Ivermectin Prescriptions for COVID-19. Insurer spending estimated at $2.5 million in the week of August 13, 2021, would extrapolate to $129.7 million annually. The true amount of waste is even higher because estimates did not include Medicaid spending.
November 26, 2021 - The World Health Organization (WHO) recently reported: "Despite pandemic challenges, health workers managed to deliver ivermectin treatment to more than 112 million people," stated Dr. Daniel Argaw Dagne, Unit head, Prevention, Treatment and Care, WHO Department of Control of Neglected Tropical Diseases.
November 23, 2021 - Medpage Today published the results of a pilot trial. The idea was to fill bird feeders with ivermectin-treated bird feed to see if this treated bird feed would reduce the number of infectious mosquitoes that could transmit the West Nile virus to humans. Karen Holcomb, Ph.D., of the University of California Davis, hypothesized that because Ivermectin had mosquitocidal properties and low toxicity in mammals and birds, it might be possible to treat bird-feeders with Ivermectin, where the mosquitoes would bite the birds, ingest the Ivermectin, and die before the virus could be transmitted to humans.
November 18, 2021 - Medpage Today published an article discussing the significant progress against the transmission of onchocerciasis, or river blindness, in several Nigerian states. Mass drug administration of Ivermectin is being credited for this progress.
October 20, 2021 - The NEJM published a Correspondence: Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19. Cases in Oregon illustrate the potentially toxic effects of Ivermectin, including severe episodes of confusion, ataxia, seizures, and hypotension, and the increasing frequency of inappropriate use. In addition, there is insufficient evidence to support the use of Ivermectin to treat or prevent Covid-19, and improper use, as well as the possible occurrence of medication interactions, may result in serious side effects requiring hospitalization.
October 18, 2021 - The Lancet Infectious Diseases published: Long-term consequences of the misuse of ivermectin data.
October 4, 2021 - The Royal Society of Chemistry published their paper on the microscopic interactions between Ivermectin and key human and viral proteins involved in SARS-CoV-2 infection.
October 1, 2021 - The Onchocerciasis Elimination Program for the Americas (OEPA) was created at the end of 1993 to eliminate onchocerciasis from the Americas. Its objectives are to provide technical and supplemental financial assistance to the elimination programs of the six endemic countries: Brazil, Colombia, Ecuador, Guatemala, Mexico, and Venezuela. According to an analysis in 2020 of administrative units that had achieved at least 20 cumulative rounds of ivermectin treatment and coverage of at least 85% of the eligible population.
September 24, 2021 - The Indian Council of Medical Research dropped Ivermectin from the approved COVID-19 treatment protocol.
September 9, 2021 - In an episode of "AMA COVID-19 Update," Dr. Farley discussed the drug's safety concerns, its potential side effects, and the vital role of physicians in guiding the unvaccinated to better choices.
September 3, 2021 - The U.S. FDA published: Why You Should Not Use Ivermectin to Treat or Prevent COVID-19.
August 26, 2021 - The U.S. CDC issued a Health Advisory stating: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19.
August 24, 2021 - Oregon Poison Center at OHSU experiences a substantial increase in calls involving intentional misuse of Ivermectin.
January 20, 2021 - Nature published results of the identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Ivermectin exhibited complete inhibition of SARS-CoV-2 3CLpro enzymatic activity blocking viral replication of SARS-CoV-2 by more than 80%.
April 27, 2018 - A systematic literature review and meta-analysis on the efficacy and safety of ivermectin-albendazole co-administration in five different databases (i.e. PubMed, ISI Web of Science, ScienceDirect, CENTRAL and clinicaltrials.gov) from 1960 to January 2018.
May 10, 2015 - The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one-half jointly to William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites.
Ivermectin Clinical Trials
Ivermectin (Stromectol, Mectizan) has been tested in over 190 clinical trials, including 78 studies using Ivermectin to treat COVID-19.